Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) & Region - Global Forecast to

Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) & Region - Global Forecast to 2028

The global leukapheresis products market is predicted to reach USD 100 million by 2028 from USD 70 million in 2023, at a CAGR of 8.3%. The global leukopaks market is predicted to reach USD 1020 million by 2028 from USD 200 million in 2023, at a CAGR of 38.1%. Due to the cases of leukemia rising globally, and rising need for leukopaks in clinical trials and other research applications, the leukapheresis market is expected to grow in the forecast period.

“The research applications accounted for a larger share of the leukapheresis products market.”

By, application, the leukpaheresis products market is segmented into research applications and therapeutic applications. The research applications segment accounted for the larger share of the leukapheresis products market in 2022. The growing development of cell-based immunotherapies and rising demand for leukapheresis-derived primary cells in drug development are some of the major factors driving the growth of the leukapheresis products market during the forecast period.

“The academic & research institutes segment accounted for the largest share of the leukopaks market.”

By end user, the leukopaks market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations. In 2022, the academic & research institutes segment accounted for the largest share of the leukapheresis products market. The increasing number of industry-academic partnerships for conducting research on cell-based cancer therapies is driving the growth of this end-user segment.

“Asia Pacific will grow at highest CAGR during the forecast period.“

In 2022, Asia Pacific will grow at highest CAGR during the forecast period. The Asia Pacific region is expected to be the fastest growing region in the forecast period. The increasing CAR-T cell therapy research and rising number of pharma & biotech companies and research institutes in China are some of the factors driving market growth. In 2022, China accounted for the largest share of the Asia Pacific leukopaks market. The large share of China can be attributed mainly to the presence of a number of cellular immunotherapy companies in the country.

The break-up of the profile of primary participants in the leukapheresis products market: Supply-side

By Company Type (Supply-side): Tier 1: 35%, Tier 2: 30%, and Tier 3: 35%

By Designation: C-level: 30%, Director-level: 30%, and Others: 40%

By Region: North America: 45%, Europe: 25%, Asia-Pacific: 20%, and Rest of the World: 10%

The break-up of the profile of primary participants in the leukopaks market: Supply-side

By Company Type (Supply-side): Tier 1: 44%, Tier 2: 36%, and Tier 3: 20%

By Designation: C-level: 44%, Director-level: 33%, and Others: 23%

By Region: North America: 40%, Europe: 25%, Asia-Pacific: 20%, and Rest of the World: 15%

Prominent players in the leukapheresis products market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany).

Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US).

Research Coverage:

The report analyzes the leukapheresis market and aims at estimating the market size and future growth potential of this market based on various segments such as product, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall leukapheresis market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

Analysis of key drivers (rising incidence and prevalence of leukemia, increasing number of blood donations, increased demand for leukopaks in clinical research), restraints (high cost of therapeutic leukapheresis and leukopaks, stringent donor recruitment criteria, complications associated with therapeutic leukapheresis), opportunities (leukapheresis for pediatric patients, emerging economies with investments from academic institutes, pharma-biotech companies, and leading players), and challenges (blood transfusion safety in emerging countries) influencing the growth of the leukapheresis market

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the leukapheresis market

Market Development: Comprehensive information on the lucrative emerging markets by type, usage, end user and region.

Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global leukapheresis market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players like Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany) in the global leukapheresis market.